Optimizing TKI Therapy for Chronic Phase CML: Sequencing of TKI Therapy and Treatment-free Remission
The availability of multiple tyrosine kinase inhibitors (TKIs) for the treatment of newly diagnosed chronic phase chronic myeloid leukemia (CML) poses significant challenges to the clinicians in terms of selection of initial TKI therapy and sequencing TKI therapy in patients with intolerance to t
Category
  • Chronic Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation
NCCN Guidelines® Updates: Discontinuing TKI Therapy in the Treatment of Chronic Myeloid Leukemia
Data from recent clinical studies indicate that discontinuation of TKI therapy (with close monitoring) may be feasible in carefully selected patients with chronic phase CML (CP-CML), prompting the introduction of a new concept known as treatment-free remission (TFR).
Category
  • Chronic Myelogenous Leukemia
Format
  • Recorded Webcast
Credits
  • AAPA Category 1 CME credit
  • ACPE contact hours
  • AMA PRA Category 1 Credit™
  • ANCC contact hours
  • Participation